Skip to content
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Viskase Holdings, Inc. VISK

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-3.4M
▼ 538.2% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income 0.8
100M200M-10M-20M
2009201220152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -5103.8% · Net ·
-2000%-4000%
200920172025
ROE
FY2022 · ROE -4.5%
50%100%150%-5%-10%-15%
200920172025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -12%.

Cash & shareholders

USD 1.3M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2013 · FCF 14.0
10M20M-5M-10M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends 1.3 · Net buybacks ·
50M100MDividendsNet buybacks
200920112013201520172019202120242025

USD 1.3M in dividends went back to shareholders in a year without profit.

Total assetsUSD 42.8M
EquityUSD -2.5M
CashUSD 42.6M
Current ratio58.57×

Equity funds -6% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VISK, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B◌0.0◌0.00.00.00.00.00.00.00.00.00.00.00.00.10.1
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.00.00.00.0−0.0−0.0−0.0−0.1
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌◌0.00.0−0.00.0◌
Income tax $B0.00.0−0.0−0.00.00.00.00.00.00.0−0.00.0−0.0−0.00.0−0.0−0.0
Net income $B−0.00.00.0−0.0−0.0−0.0−0.00.00.0−0.00.00.00.0−0.0−0.00.20.0
Free cash flow $B◌◌◌◌◌◌◌◌◌◌◌◌0.00.0−0.00.00.0
EPS, diluted $−0.070.010.00−0.02−0.03−0.03−0.020.130.12−0.030.490.650.38−0.06−0.403.030.02
Dividend / sh $◌◌◌◌◌◌◌◌◌0.150.850.002.052.002.000.00◌
Payout %−3716493—−0−0−8130122−58917415495−3139−0——
ROE %———−4.5−7.7−19.5−9.348.555.9−7.990.7165.243.9−2.0−7.892.01.3
Shares out B0.070.070.070.070.070.070.040.040.040.040.040.040.040.040.050.06◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image